PFK-158

N/A

Report date: 2024/06/27 20:00:09
NME

Base Information

Drug NamePFK-158
Drug Alias NamePFK-158ACT-PFK-158
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Action6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 inhibitors
Targets6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3
Therapy Area/IndicationsLymphoma, FollicularNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Louisville
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer Institute
Inactive CompaniesAdvanced Cancer Therapeutics Llc
Active IndicationsLymphoma, Follicular
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A